Price$1.15-0.04 (-3.36%)
01:30 PM07:45 PM
News · 26 weeks56+633%
2025-12-072026-05-31
Mix4390d
- Insider20(47%)
- SEC Filings10(23%)
- Other7(16%)
- Earnings3(7%)
- Offering3(7%)
Latest news
25 items- PRINOVIO to Participate in Upcoming Scientific and Investor ConferencesPLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific and investor conferences: Jefferies Global Healthcare Conference (New York) Date: Thursday, June 4 Time: 8:45 AM ET Format: Fireside Chat Webcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/adRiTkvKf4AnDsZYyXatz8 World Orphan Drug Congress (Boston) Poster P
- INSIDERSEC Form 4 filed by Director Yarno Wendy L4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERSEC Form 4 filed by Director Shepard Jay4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERSEC Form 4 filed by Director Miller Ann Calby4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERSEC Form 4 filed by Director Weiner David B.4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERSEC Form 4 filed by Director Zoth Lota S.4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERSEC Form 4 filed by Director Dansey Roger D4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERSEC Form 4 filed by Director Benito Simon X4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERChief Scientific Officer Humeau Laurent converted options into 6,027 shares and covered exercise/tax liability with 2,163 shares, increasing direct ownership by 9% to 46,823 units (SEC Form 4) (for withholding tax)4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERChief Medical Officer Sumner Michael John converted options into 9,450 shares and covered exercise/tax liability with 2,693 shares, increasing direct ownership by 19% to 42,038 units (SEC Form 4) (for tax liability)4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERChief Executive Officer Shea Jacqueline Elizabeth converted options into 28,296 shares and covered exercise/tax liability with 12,306 shares, increasing direct ownership by 17% to 111,021 units (SEC Form 4) to satisfy withholding obligation4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERCFO Kies Peter converted options into 8,700 shares and covered exercise/tax liability with 4,688 shares, increasing direct ownership by 10% to 42,854 units (SEC Form 4) (for tax liability)4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- PRPositive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in ChinaResults provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidateApolloBio's new clinical results further highlight the potential of INOVIO's DNA medicine platform to treat diseases caused by infection with various strains of the human papillomavirus (HPV), eliminating or reducing the need for surgical interventionsPLYMOUTH MEETING, Pa., May 21, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its partner for VGX-3100 in
- SECSEC Form 8-K filed by Inovio Pharmaceuticals Inc.8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
- INSIDERChief Executive Officer Shea Jacqueline Elizabeth converted options into 17,744 shares and covered exercise/tax liability with 7,717 shares, increasing direct ownership by 12% to 95,031 units (SEC Form 4) to cover taxes4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERCFO Kies Peter converted options into 4,771 shares and covered exercise/tax liability with 2,571 shares, increasing direct ownership by 6% to 38,842 units (SEC Form 4) (for tax liability)4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERChief Scientific Officer Humeau Laurent converted options into 4,771 shares and covered exercise/tax liability with 1,712 shares, increasing direct ownership by 8% to 42,959 units (SEC Form 4) to cover withholding tax4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERChief Medical Officer Sumner Michael John converted options into 2,385 shares and covered exercise/tax liability with 680 shares, increasing direct ownership by 5% to 35,281 units (SEC Form 4) (for tax liability)4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inovio Pharmaceuticals Inc.SCHEDULE 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)
- SECInovio Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
- PRINOVIO Reports First Quarter 2026 Financial Results and Recent Business HighlightsBiologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial readiness plans continue to advance in anticipation of a potential commercial launch for INO-3107 as a treatment for adults with Recurrent Respiratory Papillomatosis (RRP)Clinical trial collaboration and supply agreement announced with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for the potential treatment of glioblastoma (GBM) in a Dana-Farber Cancer Institute-sponsored trialCurrent cash, cash equivalents, and short-term invest
- SECSEC Form 10-Q filed by Inovio Pharmaceuticals Inc.10-Q - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
- PRINOVIO to Participate in Upcoming Scientific ConferencesPLYMOUTH MEETING, Pa., May 8, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences: American Society of Gene and Cell Therapy Annual Meeting (Boston)Poster Presentation: Bleeding phenotype correction in hemophilia A mice following in vivo Factor VIII gene transfer by electroporation in skeletal muscle cellsDate: Tuesday, May 12Time: 5 - 6:30
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inovio Pharmaceuticals Inc.SCHEDULE 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)
- PRINOVIO to Report First Quarter Financial Results on May 13, 2026PLYMOUTH MEETING, Pa., May 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its first quarter 2026 financial results will be released after the market close on May 13th, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available online at http://ir.i
INO FAQ
6 questionsWhat does Inovio Pharmaceuticals Inc. do?
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines...Where does INO stock trade?
Inovio Pharmaceuticals Inc. (INO) is listed on NASDAQ.What sector and industry is INO in?
Inovio Pharmaceuticals Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about INO?
Inovio Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $500.00 price target on 2025-07-09.What companies are similar to INO?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare INO side-by-side with any of them on Quantisnow.How can I track INO on Quantisnow?
Quantisnow aggregates Inovio Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INO to receive live email and push alerts on every new disclosure.